WhaleCreep
Home › Funds › Decheng Capital LLC › Q4 2025

Decheng Capital LLC 13F holdings, Q4 2025

Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →

Decheng Capital LLC disclosed 19 US equity positions worth $743.4m in its Q4 2025 13F filing. The largest position was CGON at 35.6% of the reported book, followed by NUVB and UPB. Against the Q3 2025 filing, it opened 0 new positions, added to 1 and reduced 9 among the top 19 holdings.

← Q3 2025 · Q1 2026 →

What did Decheng Capital LLC own in Q4 2025? Top 19 positions

#StockSectorWeightValueSharesΔ sharesvs Q3 2025
1 CGON CG ONCOLOGY INC Healthcare 35.6%$264.6m6,371,669 0% held
2 NUVB Nuvation Bio Inc. Healthcare 31.3%$232.6m25,954,439 0% held
3 UPB Upstream Bio Inc. 11.5%$85.3m3,143,078 -4% reduced
4 AARD AARDVARK THERAPEUTICS INC 6.9%$51.4m3,917,299 0% held
5 LYEL Lyell Immunopharma, Inc. 2.9%$21.3m692,050 16% added
6 NEWAMSTERDAM PHARMA CO NV 2.8%$20.8m592,057 -10% reduced
7 RVMD REVOLUTION MEDICINES INC(NSM) Healthcare 2.1%$15.9m200,000 -5% reduced
8 RCUS Arcus Biosciences, Inc Healthcare 1.7%$12.9m541,559 -1% reduced
9 ACRS Aclaris Therapeutics, Inc. Healthcare 1.6%$12.2m4,041,736 0% held
10 EQ Equillium Inc. 0.9%$6.9m4,447,308 0% held
11 BYSI BeyondSpring Inc. 0.8%$6.2m3,800,702 -11% reduced
12 CRNXGBP CRINETICS PHARMACEUTICALS IN 0.6%$4.3m92,700 -35% reduced
13 KRYS KRYSTAL BIOTECH INC Healthcare 0.6%$4.3m17,300 -46% reduced
14 AURA Aura Biosciences, Inc. 0.3%$2.0m360,483 -30% reduced
15 ZNTL Zentalis Pharmaceuticals Inc. Healthcare 0.2%$1.8m1,323,327 0% held
16 PYXS Pyxis Oncology, Inc (formerly Apexigen) 0.1%$375.8k326,810 0% held
17 FDMT 4D MOLECULAR THERAPEUTICS IN 0.0%$332.3k44,311 -52% reduced
18 Nuvation Bio Inc. 0.0%$213.2k646,057 0% held
19 RZLT REZOLUTE INC 0.0%$141.4k59,900 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.